Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation

NCT ID: NCT00721136

Last Updated: 2017-08-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 104 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-09-30
• Study Completion Date: 2010-08-31

Brief Summary

Patients requiring long term anticoagulation often undergo transition of their warfarin to heparin in anticipation of invasive surgical procedures such as pacemaker or ICD implantation. This may require inpatient hospitalization several days prior to and after the procedure, potentially increasing medical costs and patient inconvenience. Patients undergoing such a process are initiated on heparin while their INRs drift to normal levels. Immediately prior to surgery, heparin is discontinued and restarted several hours after the procedure. Unfortunately, this process has resulted in a high incidence of surgical wound hematomas and other bleeding complications often requiring longer periods of discontinued anticoagulation or repeat surgical exploration. Previous investigators have tried to reduce the incidence of wound hematomas by prolonging the time from surgical wound closure to the reinitiation of heparin. A small randomized trial demonstrated that there was no significant difference in the incidence of wound hematomas whether heparin was started 6 hours or 24 hours after surgery (J Am Coll Cardiology 2000;35:1915-8). This has led many investigators to perform pacemaker and ICD implantation without reversal of warfarin therapy. A recent retrospective observational study demonstrated that the incidence of wound hematomas in patients with an INR of 2.6 was no different than patients with an INR of 1.5 (PACE 2004;27:358-60). Furthermore, a more recent, larger retrospective observational study reported in abstract form at the recent Heart Rhythm Society Annual 2007 Scientific Meeting demonstrated that not only is performing pacemaker and ICD implantations safe without reversing warfarin anticoagulation, but the incidence of wound hematomas is significantly smaller as compared to the strategy of reversing warfarin and initiating periprocedural heparin.

Given these findings, the hypothesis of this randomized study is that pacemaker and ICD implantation while fully anticoagulated on warfarin therapy is safe. Findings from this study will have significant implications on the clinical practice of pacemaker or ICD implantation in this patient population given that no randomized study on this subject has been performed to date.

Conditions

Bradycardia; Tachycardia; Atrial Fibrillation; Valvular Heart Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

1

Moderate risk patients (afib, mechanical aortic valve) randomized to continue coumadin at their usual dose through the procedure.

Group Type: EXPERIMENTAL

continue warfarin through the procedure

Intervention Type: DRUG

The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.

2

Moderate risk patients randomized to hold their coumadin for 4-5 days prior to the procedure (to allow the INR to normalize).

Group Type: ACTIVE_COMPARATOR

Hold warfarin

Intervention Type: DRUG

For moderate risk patients, warfarin will be held for 4-5 days prior to the procedure.

3

High risk patients (mechanical mitral valve, prior stroke, current deep vein thrombosis, hypercoagulable syndrome) randomized to continue coumadin at the usual dose through the procedure.

Group Type: EXPERIMENTAL

continue warfarin through the procedure

Intervention Type: DRUG

The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.

4

High risk patients randomized to holding coumadin for 4-5 days and using "bridging" anticoagulation with heparin while the coumadin is held.

Group Type: ACTIVE_COMPARATOR

Warfarin held with heparin transition.

Intervention Type: DRUG

For high risk patients, warfarin is held for 4-5 days prior to the procedure and heparin is given to provide anticoagulation while the INR is subtherapeutic.

Interventions

continue warfarin through the procedure

The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.

Intervention Type: DRUG

Hold warfarin

For moderate risk patients, warfarin will be held for 4-5 days prior to the procedure.

Intervention Type: DRUG

Warfarin held with heparin transition.

For high risk patients, warfarin is held for 4-5 days prior to the procedure and heparin is given to provide anticoagulation while the INR is subtherapeutic.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• scheduled for clinically indicated permanent pacemaker or implantable cardioverter-defibrillator
• currently on chronic warfarin therapy

Exclusion Criteria

• unwilling to participate in trial

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Johns Hopkins University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alan Cheng, MD

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins University

Locations

Johns Hopkins Bayview Medical Center

Baltimore, Maryland, United States

Howard County General Hospital

Columbia, Maryland, United States

Countries

United States

Other Identifiers

NA_00011273

Identifier Type: -

Identifier Source: org_study_id